Ascending and descending efferent projections of superior coUiculus were indentified by means of the anterograde horseradish peroxidase technique in the cat.Following injections of HRP into the rostral superior colliculus, a large number of labeled terminals were found mainly in several of the ipsilateral thalamic nuclei:ventromedial division of the ventral nucleus of the lateral geniculate body, zona incerta,lateral posterior nucleus, parafasciculus nucleus and centromedian nucleus. The mediodorsal nucleus and thalamic reticular nucleus were also found mildly labeled.Labeling were most heavily concentrated in the ipsilateral dorsolateral division of pontine nucleus and caudal region of parabigeminal nucleus. The dorsal part of medial accessory olivary was the only nucleus labeled contralaterally. After injecting HRP into the caudal superior colliculus, only the dorsolateral division of pontine nucleus was densely labeled, while labeled terminals of caudal parabigeminal nucleus signifcantly reduced in amount. No labeled terminals were found in the thalamus as well as medial accessory olivary nucleus. These results indicate that the efferent connections of superior colliculus are topographically organized.

The different distributions of substance P(SP)-and leucine-enkephalin (L-ENK)-like immunoreactive neurons in the midbrain raphe nuclei of the rats have been studied, using PAP immunocytochemical technique. The results showed four main points: 1. SP-containing immunoreactive cell bodies were only seen in the most caudal part of the dorsal raphe nucleus, the average number of SP-positive cell bodies was about 167 in each animal. The L-ENK-like immunoreactive positive cell bodies were found almost in the whole length of the dorsal raphe nucleus, the L-ENK-positive cell bodies were about 132 in each animal. 2. L-ENK-Iike immunoreactive perikarya were mainly located in the midline area of the dorsal raphe nucleus. Besides the above areas, SP-containing immunoreactive cell bodies were also located bilaterally in the extended area from the raphe. 3. L-ENK-containing immunoreactive cell bodies constantly appeared in the median raphe nuclei, the average number was about 199 in each animal, but SP-containing immunoreactive bodies were only observed in this nucleus of two rats. 4. Some SP-like immunoreactive cell bodies or processes were observed in the vincinty of vascular walls, but the L-ENK positive neurons were not found similar results. The present experiment showed that the SP-like immunoreactive perikarya is located in the median raphe nuclei of the rat.

The topographical projection between the parabigeminal nucleus and the superiorcolliculus in the cat was investigated by retrograde and anterograde HRP tracingtechnique.Following HRP injection in the rostral superior colliculus,the labeledsomata were found predominantly in the rostral region of contralateral parabigeminalnucleus,but labeled terminals were heavily distributed in the ipsilateral parabigeminalnucleus,mainly in the caudal region.Following injection of HRP into caudal superiorcolliculus,the labeled somata and terminals were seen in ipsilateral parabigeminalnucleus,chiefly in caudal part,but their number was significantly decreased.It wasnoted that the labeled somata were sparse but labeled terminals were not found inthe parabigeminal nucleus,when the injection was restricted to superficial layers ofsuperior colliculus.After HRP injection into deeper layers of superior colliculus,there existed not only the labeled somata but also the labeled terminals in theparabigeminal nucleus,the former was distributed in bilateral parabigeminal nucleus,the latter in ipsilateral nucleus,chiefly in the caudal part.These results show thatthere are topographical connections between the parabigeminal nucleus and superiorcolliculus,and the parental somata contributing axons to the parabigeminal nucleusare located in deeper layers of the ipsilateral superior colliculus.

The present investigation was performed on six adult cats. The morphology and distribution of the labeled cells in the ventral lateral geniculate nucleus (LGNv) were observed. Following the injection of horseradish peroxidase (HRP) into the deeper layers of the superior colliculus the labeled cells were found to concentrate ipsilaterally in the ventral part of the rostromedial division of the LGNv. The HRP-positive cells were composed of large-sized, smaller, round and oval ceils. In the cases of injection of HRP into the rostral pretectum, the HRP-positive cells were seen bilaterally in the caudolateral division of LGNv mainly in the contralateral part, while the labeled cells were found ipsilaterally in the ventral part of caudolateral division after injection of HRP into the caudal pretectum. These cells were smaller than that large ones of superior colliculus injection. The results indicate that the projection of the LGNv to the superior colliculus and pretectum is organized topographically.

Objective:To construct a novel respiratory syncytial virus (RSV) vaccine based on a recombinant influenza virus vector and evaluate its immune protective effects in mice.Methods:A recombinant H1N1 influenza A virus (IAV) expressing the extracellular domain (Gecto) of RSV A2 G protein was constructed and rescued, named as PR8NAGecto/WSN. After in vitro verification of the Gecto expression and PR8NAGecto/WSN growth kinetics, a single dose of PR8NAGecto/WSN was used to immunize BALB/c mice through intranasal administration to evaluate the efficacy of PR8NAGecto/WSN by assessing humoral (IgG, neutralizing antibody), mucosal (IgA) and cellular immunity (IFN-γ ELISPOT). Four weeks after immunization, the mice were challenged with RSV A2 or RSV B9320 to evaluate the protective effects of PR8NAGecto/WSN by analyzing mouse body weight changes, lung tissue virus titers and pathological changes. Results:A single-dose intranasal immunization with PR8NAGecto/WSN induced robust humoral, mucosal and cellular immunity in mice. Moreover, the mice in the immunized group had lower lung virus loads and mild lung pathological damages following the challenge with RSV A or RSV B subtype as compared with the control group.Conclusions:A single-dose intranasal immunization with PR8NAGecto/WSN induces robust immunity and provide protection against RSV A and B challenges in mice. This study provides new ideas and reference for the development of novel mucosal vaccines against RSV.

OBJECTIVE To provide reference for improving resource carrying capacity of pharmaceutical industry and guaranteeing the healthy and sustainable development of pharmaceutical industry of China. METHODS The evaluation system of resource carrying capacity was constructed ，including 4 primary indicators and 17 secondary indicators. The data of above indicators were selected from 31 provinces（autonomous regions and municipalities ）（hereinafter referred to as provinces ）of China during 2013-2020. The index weight and regional relevance were calculated by entropy weight technique for order preference by similarity to ideal solution（TOPSIS）method. RESULTS & CONCLUSIONS The weights of 4 primary indicators were 0.182 0 （industrial scale ），0.349 5（industrial innovation resources ），0.211 5（economic resources ）and 0.257 1（industrial development foundation）. It indicated that industrial innovation resources were the main factor affecting the resource carrying capacity of pharmaceutical industry ，followed by industrial development foundation and economic resources ，and the impact of industrial scale was the least. From 2013 to 2016 and from 2018 to 2020，the average closeness of the pharmaceutical industry in China ’s provinces were 0.259 6，0.267 1，0.253 6，0.249 9，0.250 5，0.248 5 and 0.252 0，respectively. It indicated that the resource carrying capacity of China ’s pharmaceutical industry showed a stable development trend ，but the overall development was in low level. The top 5 regions in terms of closeness of carrying capacity were Jiangsu ，Guangdong，Shandong，Zhejiang and Beijing ；the regions in the bottom 5 were Gansu ，Hainan，Qinghai，Tibet and Ningxia. Overall ，the resource carrying capacity of China ’s pharmaceutical industry showed a gradual decreasing trend from the eastern coastal area to the western inland area. For the provinces with the highest resource carrying capacity of pharmaceutical industry ，further development can be carried out on the basis of maintaining the original carrying capacity ；for the provinces with the middle resource carrying cap acity of p harmaceutical industry ，enhancing the development potential and improving the industrialfoundation are the main methods to improve the resource carrying capacity of pharmaceutical industry ；for the provinces wangjl@126.com with low resource carrying capacity of pharmaceutical industry ， it can be considered to start from their own unique advantages ， make full use of characteri stic industrial resources ，form a characteristic industrial foundation ，actively promote interregional cooperation ，implement regional cluster development and improve the resource carrying capacity of pharmaceutical industry.